Lucid Diagnostics’ (NASDAQ:LUCD) EsoGuard test could get Medicare coverage soon, according to recent commentary from BTIG analysts.

Analysts at BTIG said that during a day of investor meetings with Lucid’s executive team, it became clear that the company’s minimally invasive EsoGuard